Arete Wealth Advisors, LLC Surface Oncology, Inc. Transaction History

Arete Wealth Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$0.57 - $0.88 $285 - $440	500 Added 0.93%	54,465 $47,000
Q1 2023 May 01, 2023	SELL	$0.61 - $1.03 $4,996 - $8,436	-8,191 Reduced 13.18%	53,965 $37,000
Q4 2022 Feb 06, 2023	BUY	$0.62 - $1.21 $3,078 - $6,008	4,966 Added 8.68%	62,156 $50,000
Q3 2022 Nov 07, 2022	SELL	$1.05 - $2.1 $5,684 - $11,369	-5,414 Reduced 8.65%	57,190 $59,000
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $12,058 - $26,749	8,492 Added 15.69%	62,604 $103,000
Q1 2022 May 06, 2022	SELL	$2.65 - $5.08 $4,491 - $8,610	-1,695 Reduced 3.04%	54,112 $159,000
Q4 2021 Feb 07, 2022	BUY	$4.73 - $7.9 $263,967 - $440,875	55,807 New	55,807 $283,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $7.98 $81,192 - $125,565	-15,735 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$6.45 - $9.09 $101,490 - $143,031	15,735 New	15,735 $103,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Arete Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Arete Wealth Advisors, LLC with notifications on news.